VTRS Viatris
Viatris is a global healthcare company formed in November 2020 through the combination of Mylan and the Upjohn Business whose mission is to empower people worldwide to live healthier at every stage of life. By integrating the strengths of these two businesses, including our global workforce of approximately 45,000 employees and contractors, Viatris aims to deliver increased access to affordable, quality medicines for patients worldwide regardless of geography or circumstance. Viatris brings together industry leading commercial, R&D, regulatory, manufacturing, legal and medical expertise complemented by a strong commitment to quality and unparalleled geographic footprint to deliver high-quality medicines to patients in more than 165 countries and territories. Viatris’ portfolio comprises more than 1,400 approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generic, complex generic and biosimilars. Viatris operates approximately 50 manufacturing sites worldwide that produce oral solid doses, injectables, complex dosage forms and APIs. Viatris is headquartered in the U.S., with global centers in Pittsburgh, Pennsylvania, Shanghai, China and Hyderabad, India.
Company profile
Ticker
VTRS
Exchange
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
Upjohn Inc
SEC CIK
Corporate docs
IRS number
834364296
VTRS stock data
()
News
Stocks That Hit 52-Week Lows On Thursday
8 Apr 21
Analyzing Viatris's Unusual Options Activity
18 Mar 21
Morgan Stanley Maintains Equal-Weight on Viatris, Lowers Price Target to $16
10 Mar 21
Benzinga's Top Ratings Upgrades, Downgrades For March 8, 2021
8 Mar 21
10 Biggest Price Target Changes For Monday
8 Mar 21
Press releases
Viatris Inc. to Release First Quarter 2021 Financial Results on May 10, 2021
12 Apr 21
Viatris Inc. and Kindeva Drug Delivery Announce FDA Tentative Approval of the First Abbreviated New Drug Application Generic Version of Symbicort® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol
8 Mar 21
Viatris Inc. to Participate in Barclays Global Healthcare Conference
4 Mar 21
Viatris Inc. Hosts Inaugural Investor Day Outlining Unique and Differentiated Business Model, High-Quality Operational Platform, and Focus on CSR and Financial Commitments
1 Mar 21
Thinking about buying stock in Viatris, Energous Corp, Marathon Oil, Norwegian Cruise Line, or Snap?
22 Feb 21
Calendar
1 Mar 21
12 Apr 21
31 Dec 21
Financial summary
Quarter (USD) |
Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) |
Dec 20 | Dec 19 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Financial data from Viatris earnings reports.
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
3 Mar 21 | Cornwell W Don | Common Stock | Buy | Aquire P | No | No | 13.8383 | 3,000 | 41.51K | 3,000 |
2 Mar 21 | der Meer Mohr Pauline van | Common Stock | Option exercise | Aquire M | No | No | 0 | 9,440 | 0 | 15,705 |
2 Mar 21 | der Meer Mohr Pauline van | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 9,440 | 0 | 0 |
2 Mar 21 | der Meer Mohr Pauline van | RSU Common Stock | Grant | Aquire A | No | No | 0 | 13,996 | 0 | 13,996 |
2 Mar 21 | Cornwell W Don | RSU Common Stock | Grant | Aquire A | No | No | 0 | 13,996 | 0 | 13,996 |
2 Mar 21 | Kilts James M | RSU Common Stock | Grant | Aquire A | No | No | 0 | 13,996 | 0 | 13,996 |
2 Mar 21 | Neil F Dimick | Common Stock | Option exercise | Aquire M | No | No | 0 | 9,440 | 0 | 60,703 |
2 Mar 21 | Neil F Dimick | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 9,440 | 0 | 0 |
2 Mar 21 | Neil F Dimick | RSU Common Stock | Grant | Aquire A | No | No | 0 | 13,996 | 0 | 13,996 |
2 Mar 21 | Brian Roman | Common Stock | Payment of exercise | Dispose F | No | No | 14.29 | 2,195 | 31.37K | 38,676 |
Institutional ownership Q4 2020
Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.
76.9% owned by funds/institutions
13F holders |
Current |
---|---|
Total holders | 1140 |
Opened positions | 1140 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares |
Current |
---|---|
Total value | 17.4B |
Total shares | 928.65M |
Total puts | 20.27M |
Total calls | 13.41M |
Total put/call ratio | 1.5 |
Largest owners |
Shares | Value |
---|---|---|
Vanguard | 129.07M | $2.42B |
BLK Blackrock | 89.53M | $1.68B |
Wellington Management | 69.81M | $1.31B |
STT State Street | 52.54M | $984.6M |
MCQEF Macquarie | 38.41M | $719.83M |
Capital World Investors | 33.27M | $623.43M |
Laurion Capital Management | 23.23M | $435.41M |
Geode Capital Management | 22.77M | $425.75M |
PZN Pzena Investment Management | 17.09M | $320.25M |
Deerfield Management | 15.72M | $294.67M |
Financial report summary
?Competition
Coherus BiosciencesContent analysis
?
Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
Current reports
8-K/A
Cost Associated with Exit or Disposal Activities
25 Feb 21
8-K
Results of Operations and Financial Condition
22 Feb 21
8-K/A
Financial Statements and Exhibits
29 Jan 21
8-K/A
Cost Associated with Exit or Disposal Activities
11 Dec 20
8-K
Entry into a Material Definitive Agreement
25 Nov 20
8-K/A
Entry into a Material Definitive Agreement
19 Nov 20
8-K
Entry into a Material Definitive Agreement
19 Nov 20
8-K
Regulation FD Disclosure
6 Aug 20
8-K
Entry into a Material Definitive Agreement
26 Jun 20
8-K
Entry into a Material Definitive Agreement
16 Jun 20
Registration and prospectus
S-8
Registration of securities for employees
20 Nov 20
8-A12B
Registration of securities on exchange
10 Nov 20
425
Business combination disclosure
26 Jun 20
425
Business combination disclosure
18 Jun 20
425
Business combination disclosure
16 Jun 20
10-12G
Registration of securities
12 Jun 20
425
Business combination disclosure
1 Jun 20
425
Business combination disclosure
29 May 20
RW
Registration withdrawal request
11 Mar 20
424B3
Prospectus supplement
13 Feb 20
Proxies
No filings
Other
EFFECT
Notice of effectiveness
14 Feb 20
CORRESP
Correspondence with SEC
10 Feb 20
CORRESP
Correspondence with SEC
5 Feb 20
UPLOAD
Letter from SEC
2 Feb 20
CORRESP
Correspondence with SEC
16 Jan 20
UPLOAD
Letter from SEC
2 Jan 20
CORRESP
Correspondence with SEC
12 Dec 19
CORRESP
Correspondence with SEC
12 Dec 19
UPLOAD
Letter from SEC
21 Nov 19
UPLOAD
Letter from SEC
21 Nov 19
Ownership
4
Viatris / Rajiv Malik ownership change
4 Mar 21
4
Viatris / ROBERT J COURY ownership change
4 Mar 21
4
Viatris / Sanjeev Narula ownership change
4 Mar 21
4
Viatris / Brian Roman ownership change
4 Mar 21
4
Viatris / RICHARD A MARK ownership change
4 Mar 21
4
Viatris / Dillon JoEllen Lyons ownership change
4 Mar 21
4
Viatris / MICHAEL GOETTLER ownership change
4 Mar 21
4
Viatris / Andrew Cuneo ownership change
4 Mar 21
4
Viatris / IAN C READ ownership change
4 Mar 21
4
Viatris / Paul Campbell ownership change
4 Mar 21
Reddit threads
Lumber DD: CNBC and Motley Fool's "Best Lumber Stocks" Unsurprisingly Are the Worst Price Performers or Are Unrelated to Lumber
8 Apr 21
Who’s going long on Pfizer (PFE)?
7 Apr 21
Wall Street Week Ahead for the trading week beginning April 5th, 2021
3 Apr 21
Daily Discussion Thread - April 1st, 2021
1 Apr 21
Daily Discussion Thread - March 31st, 2021
31 Mar 21
Daily Discussion Thread - March 30th, 2021
30 Mar 21
Daily Discussion Thread - March 29th, 2021
29 Mar 21
IBM, yess 5pct div IBM Time in the Sun has finally arrived after 18 months
27 Mar 21
What stocks focus on sexual self-satisfaction?
27 Mar 21
Daily Discussion Thread - March 25th, 2021
25 Mar 21